GLP1R and type 2 diabetes mellitus: Both ESC [1] and ACC/AHA guidelines [225] recommend GLP-1 receptor agonists as part of the secondary prevention strategy for patients with acute coronary syndrome who have type 2 diabetes or very high cardiovascular risk.